Shaily Engineering Plastics Ltd
The Company is engaged in the manufacture and sale of injection moulded precision plastic components, sub-assemblies for various requirements of Original Equipment Manufacturers (OEM).
It also offers secondary operations in plastics like vacuum metalizing, hot stamping, and ultrasonic welding. Its manufacturing facilities are at Savli and Halol, Vadodara, Gujarat. [1]
- Market Cap ₹ 12,397 Cr.
- Current Price ₹ 2,695
- High / Low ₹ 2,847 / 1,534
- Stock P/E 76.8
- Book Value ₹ 141
- Dividend Yield 0.07 %
- ROCE 30.2 %
- ROE 28.2 %
- Face Value ₹ 2.00
Pros
- Company has delivered good profit growth of 48.9% CAGR over last 5 years
Cons
- Stock is trading at 19.1 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 180 | 226 | 246 | 318 | 338 | 336 | 361 | 566 | 600 | 616 | 738 | 921 | |
| 153 | 186 | 205 | 264 | 285 | 277 | 300 | 484 | 512 | 520 | 594 | 666 | |
| Operating Profit | 26 | 39 | 41 | 54 | 53 | 59 | 60 | 82 | 88 | 96 | 144 | 255 |
| OPM % | 15% | 17% | 17% | 17% | 16% | 17% | 17% | 15% | 15% | 16% | 20% | 28% |
| 2 | 3 | 3 | 2 | 2 | 1 | 3 | 9 | 4 | 6 | 7 | 18 | |
| Interest | 7 | 10 | 8 | 8 | 10 | 11 | 14 | 18 | 19 | 19 | 18 | 16 |
| Depreciation | 6 | 10 | 13 | 14 | 15 | 18 | 20 | 26 | 33 | 35 | 39 | 45 |
| Profit before tax | 15 | 21 | 23 | 34 | 30 | 31 | 30 | 46 | 40 | 49 | 95 | 212 |
| Tax % | 13% | 28% | 32% | 30% | 36% | 23% | 26% | 24% | 25% | 26% | 25% | 24% |
| 13 | 15 | 16 | 24 | 19 | 24 | 22 | 35 | 30 | 36 | 71 | 161 | |
| EPS in Rs | 3.13 | 3.72 | 3.81 | 5.74 | 4.63 | 5.67 | 5.29 | 7.66 | 6.53 | 7.88 | 15.43 | 35.10 |
| Dividend Payout % | 13% | 21% | 26% | 26% | 0% | 0% | 0% | 0% | 0% | 13% | 13% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 21% |
| 3 Years: | 15% |
| TTM: | 25% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 28% |
| 5 Years: | 49% |
| 3 Years: | 75% |
| TTM: | 128% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 38% |
| 5 Years: | 64% |
| 3 Years: | 118% |
| 1 Year: | 49% |
| Return on Equity | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 16% |
| 3 Years: | 19% |
| Last Year: | 28% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 |
| Reserves | 70 | 81 | 97 | 116 | 128 | 151 | 174 | 358 | 386 | 422 | 487 | 640 |
| 83 | 67 | 66 | 107 | 120 | 134 | 200 | 175 | 188 | 209 | 188 | 175 | |
| 31 | 34 | 29 | 54 | 56 | 88 | 86 | 133 | 101 | 112 | 186 | 246 | |
| Total Liabilities | 192 | 191 | 200 | 285 | 312 | 381 | 467 | 676 | 685 | 752 | 871 | 1,071 |
| 77 | 97 | 94 | 108 | 145 | 157 | 227 | 329 | 362 | 453 | 477 | 591 | |
| CWIP | 1 | 0 | 4 | 6 | 5 | 46 | 30 | 29 | 55 | 17 | 18 | 29 |
| Investments | 26 | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 15 | 21 | 11 | 11 |
| 89 | 93 | 102 | 171 | 161 | 178 | 210 | 309 | 252 | 261 | 365 | 439 | |
| Total Assets | 192 | 191 | 200 | 285 | 312 | 381 | 467 | 676 | 685 | 752 | 871 | 1,071 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 | 36 | 17 | 5 | 66 | 66 | 22 | 56 | 85 | 74 | 96 | ||
| -38 | 1 | -14 | -26 | -62 | -64 | -82 | -134 | -93 | -92 | -54 | ||
| 32 | -29 | -11 | 20 | -4 | 4 | 53 | 108 | -5 | 5 | -42 | ||
| Net Cash Flow | -1 | 8 | -8 | -0 | 0 | 6 | -6 | 30 | -14 | -13 | -0 | |
| Free Cash Flow | -26 | 8 | -0 | -21 | 2 | 4 | -61 | -60 | -13 | -14 | 27 | |
| CFO/OP | 27% | 103% | 51% | 25% | 145% | 128% | 47% | 76% | 103% | 87% | 77% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 76 | 58 | 69 | 78 | 64 | 66 | 70 | 64 | 54 | 66 | 73 | 72 |
| Inventory Days | 71 | 67 | 67 | 75 | 75 | 92 | 113 | 114 | 69 | 82 | 121 | 132 |
| Days Payable | 54 | 56 | 48 | 68 | 57 | 96 | 79 | 86 | 48 | 66 | 86 | 74 |
| Cash Conversion Cycle | 93 | 70 | 87 | 85 | 83 | 62 | 105 | 92 | 75 | 82 | 108 | 130 |
| Working Capital Days | 1 | 21 | 24 | 24 | 18 | 4 | 32 | 40 | 3 | 3 | 11 | 12 |
| ROCE % | 16% | 19% | 19% | 21% | 17% | 15% | 13% | 14% | 10% | 11% | 17% | 30% |
Insights
In beta| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Volume of Polymers Processed Metric Tonnes |
|
|||||||||
| Machine Utilization % |
||||||||||
| Export Share of Revenue % |
||||||||||
| Healthcare Segment Revenue Contribution % |
||||||||||
| Number of Injection Molding Machines Units |
||||||||||
| Pen Manufacturing Capacity Million Units |
||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
2d - Intimation of Schedule of Analyst / Institutional Meeting on Thursday May 28, 2026
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
20 May - Audio recording of earnings call held on 20 May 2026 uploaded; transcript to follow.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
20 May - ShailyPen Neo device secured USFDA TA, Health Canada, India approvals; semaglutide injection launched in Canada and India.
-
Announcement under Regulation 30 (LODR)-Change in Management
19 May - Board approved FY26 audited results, ₹3 final dividend, appointed COO KMP, and enabling ₹500 crore fund raise.
-
Grant Of Employee Stock Options
19 May - NRC approved grant of 3,000 stock options under ESOP 2019 on May 19, 2026.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
May 2026TranscriptAI SummaryPPT
-
Feb 2026Transcript PPT REC
-
Nov 2025Transcript PPT REC
-
Aug 2025Transcript PPT
-
May 2025Transcript PPT
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT REC
-
Aug 2024Transcript PPT
-
Jun 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Feb 2024TranscriptAI SummaryPPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Jun 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Sep 2021TranscriptPPT
-
Aug 2021TranscriptAI SummaryPPT
-
Jun 2021Transcript PPT
-
Feb 2021TranscriptPPT
-
Nov 2020TranscriptPPT
-
Aug 2020TranscriptPPT
-
Jul 2020TranscriptPPT
-
Nov 2019TranscriptAI SummaryPPT
-
Mar 2018Transcript PPT
-
Jan 2016TranscriptAI SummaryPPT
Business Segments[1]
a) Consumer: This segment includes home furnishings, FMCG packaging, LED lights, and toys (via partnership with Spin Master). The company has been awarded new business in the Home Furnishing segment from 2 global retail chains, with supplies expected to start from Q1/Q2 FY26.